Researchers compared eurythmy therapy with slow-paced physical exercises to determine their effectiveness on fatigue in patients with metastatic breast cancer.

In this analysis from the phase 3 S1826 study, researchers aimed to show the durability of the efficacy of nivolumab plus doxorubicin, vinblastine, and dacarbazine in classic Hodgkin lymphoma.

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

Longitudinal data reveal consistent initial responsiveness to targeted agents but limited durability once patients cycle through both BTKi and BCL2i classes.

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).